Alcohol use disorder (AUD), alcohol morbidity and mortality, and low AUD treatment engagement and completion are pressing issues for American Indian and Alaska Native people. 1 Efforts to improve AUD treatment among American Indian and Alaska Native populations has long warranted more research that is culturally congruent, community based, participatory, and evidence based. However, little has been done in the way of randomized clinical trials and/or multisite research studies that acknowledge the geographic, tribal, and cultural diversity among American Indian and Alaska Native populations. In other populations, contingency management (CM) has been shown 2 to be a promising intervention to promote abstinence and increase engagement in treatment across the continuum of care for substance use disorders. Rooted in the basic behavioral principle of positive reinforcement, wherein environmental outcomes increase the probability that a desired response will be repeated in the future, CM provides rewards for biochemically validated abstinence or treatment adherence. 3 While CM has potential, prior research on its efficacy among American Indian and Alaska Native people has been limited to a singlesite proof-of-concept study among individuals with AUD who also used other drugs. 4 In this issue of JAMA Psychiatry, McDonell et al 5 reported the results of a 12-week multisite randomized clinical trial of CM for the treatment of AUD among American Indian and Alaska Native adults in which rewards were provided for abstinence verified by ethyl glucuronide (EtG), a biomarker of recent alcohol use. Four hundred individuals were enrolled in a 4-week observation and qualification period in which they could receive treatment as usual and incentives for providing urine samples twice weekly for measurement of EtG. At the end of this period, 158 participants who had provided at least 50% of scheduled urine samples and had at least 1 EtG level positive for alcohol were randomized to either contingent reinforcement (also called prize draws) for alcohol abstinence verified by EtG or a control group in which noncontingent incentives were given for providing urine samples, irrespective of EtG levels. Those randomized to CM had 1.7 times greater odds of submitting an alcohol-negative urine sample over time (odds ratio, 1.7 [95% CI, 1.1-2.8]; P = .03) compared with the control group, providing support for the efficacy of the CM intervention.